Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Morton, CA, Szeimies, R-M, Basset-Seguin, N, Calzavara-Pinton, P, Gilaberte, Y, Haedersdal, M, Hofbauer, GFL, Hunger, RE, Karrer, S, Piaserico, S, Ulrich, C, Wennberg, A-M & Braathen, LR 2019, 'European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas' Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 33, no. 12, pp. 2225-2238. https://doi.org/10.1111/jdv.16017

APA

CBE

MLA

Vancouver

Author

Morton, C A ; Szeimies, R-M ; Basset-Seguin, N ; Calzavara-Pinton, P ; Gilaberte, Y ; Haedersdal, M ; Hofbauer, G F L ; Hunger, R E ; Karrer, S ; Piaserico, S ; Ulrich, C ; Wennberg, A-M ; Braathen, L R. / European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1 : treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas. In: Journal of the European Academy of Dermatology and Venereology : JEADV. 2019 ; Vol. 33, No. 12. pp. 2225-2238.

Bibtex

@article{50385dd62c5741718df1d42494a29f21,
title = "European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas",
abstract = "Topical photodynamic therapy (PDT) is a widely approved therapy for actinic keratoses, Bowen's disease (squamous cell carcinoma in situ), superficial and certain thin basal cell carcinomas. Recurrence rates when standard treatment protocols are used are typically equivalent to existing therapies, although inferior to surgery for nodular basal cell carcinoma. PDT can be used both as lesional and field therapies and has the potential to delay/reduce the development of new lesions. A protocol using daylight to treat actinic keratoses is widely practised, with conventional PDT using a red light after typically a 3-h period of occlusion employed for other superficial skin cancer indications as well as for actinic keratoses when daylight therapy is not feasible. PDT is a well-tolerated therapy although discomfort associated with conventional protocol may require pain-reduction measures. PDT using daylight is associated with no or minimal pain and preferred by patient. There is an emerging literature on enhancing conventional PDT protocols or combined PDT with another treatment to increase response rates. This guideline, published over two parts, considers all current approved and emerging indications for the use of topical PDT in dermatology, prepared by the PDT subgroup of the European Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published evidence.",
author = "Morton, {C A} and R-M Szeimies and N Basset-Seguin and P Calzavara-Pinton and Y Gilaberte and M Haedersdal and Hofbauer, {G F L} and Hunger, {R E} and S Karrer and S Piaserico and C Ulrich and A-M Wennberg and Braathen, {L R}",
note = "{\circledC} 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.",
year = "2019",
month = "12",
doi = "10.1111/jdv.16017",
language = "English",
volume = "33",
pages = "2225--2238",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1

T2 - treatment delivery and established indications - actinic keratoses, Bowen's disease and basal cell carcinomas

AU - Morton, C A

AU - Szeimies, R-M

AU - Basset-Seguin, N

AU - Calzavara-Pinton, P

AU - Gilaberte, Y

AU - Haedersdal, M

AU - Hofbauer, G F L

AU - Hunger, R E

AU - Karrer, S

AU - Piaserico, S

AU - Ulrich, C

AU - Wennberg, A-M

AU - Braathen, L R

N1 - © 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

PY - 2019/12

Y1 - 2019/12

N2 - Topical photodynamic therapy (PDT) is a widely approved therapy for actinic keratoses, Bowen's disease (squamous cell carcinoma in situ), superficial and certain thin basal cell carcinomas. Recurrence rates when standard treatment protocols are used are typically equivalent to existing therapies, although inferior to surgery for nodular basal cell carcinoma. PDT can be used both as lesional and field therapies and has the potential to delay/reduce the development of new lesions. A protocol using daylight to treat actinic keratoses is widely practised, with conventional PDT using a red light after typically a 3-h period of occlusion employed for other superficial skin cancer indications as well as for actinic keratoses when daylight therapy is not feasible. PDT is a well-tolerated therapy although discomfort associated with conventional protocol may require pain-reduction measures. PDT using daylight is associated with no or minimal pain and preferred by patient. There is an emerging literature on enhancing conventional PDT protocols or combined PDT with another treatment to increase response rates. This guideline, published over two parts, considers all current approved and emerging indications for the use of topical PDT in dermatology, prepared by the PDT subgroup of the European Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published evidence.

AB - Topical photodynamic therapy (PDT) is a widely approved therapy for actinic keratoses, Bowen's disease (squamous cell carcinoma in situ), superficial and certain thin basal cell carcinomas. Recurrence rates when standard treatment protocols are used are typically equivalent to existing therapies, although inferior to surgery for nodular basal cell carcinoma. PDT can be used both as lesional and field therapies and has the potential to delay/reduce the development of new lesions. A protocol using daylight to treat actinic keratoses is widely practised, with conventional PDT using a red light after typically a 3-h period of occlusion employed for other superficial skin cancer indications as well as for actinic keratoses when daylight therapy is not feasible. PDT is a well-tolerated therapy although discomfort associated with conventional protocol may require pain-reduction measures. PDT using daylight is associated with no or minimal pain and preferred by patient. There is an emerging literature on enhancing conventional PDT protocols or combined PDT with another treatment to increase response rates. This guideline, published over two parts, considers all current approved and emerging indications for the use of topical PDT in dermatology, prepared by the PDT subgroup of the European Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published evidence.

U2 - 10.1111/jdv.16017

DO - 10.1111/jdv.16017

M3 - Journal article

VL - 33

SP - 2225

EP - 2238

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 12

ER -

ID: 59168609